Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine

Front Pharmacol. 2023 Mar 7;14:1147717. doi: 10.3389/fphar.2023.1147717. eCollection 2023.


Ovarian cancer (OC) remains the most fatal disease of gynecologic malignant tumors. Angiogenesis refers to the development of new vessels from pre-existing ones, which is responsible for supplying nutrients and removing metabolic waste. Although not yet completely understood, tumor vascularization is orchestrated by multiple secreted factors and signaling pathways. The most central proangiogenic signal, vascular endothelial growth factor (VEGF)/VEGFR signaling, is also the primary target of initial clinical anti-angiogenic effort. However, the efficiency of therapy has so far been modest due to the low response rate and rapidly emerging acquiring resistance. This review focused on the current understanding of the in-depth mechanisms of tumor angiogenesis, together with the newest reports of clinical trial outcomes and resistance mechanism of anti-angiogenic agents in OC. We also emphatically summarized and analyzed previously reported biomarkers and predictive models to describe the prospect of precision therapy of anti-angiogenic drugs in OC.

Keywords: angiogenesis; anti-angiogenic therapy; biomarker; ovarian cancer; precision medicine.

Publication types

  • Review

Grant support

The National Natural Science Foundation of China (No. 82003868). The National Natural Science Foundation of China (No. 82203060). Scientific Research Projects of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (No. 2022xhyn055). Hubei Provincial Natural Science Foundation of China (No. 2020CFB388). Hubei Provincial Natural Science Foundation of China (No. 2022CFB592).